Mini-Focus Issue: Acute Coronary Syndromes
Clinical Research
Use of Invasive Strategy in Non–ST-Segment Elevation Myocardial Infarction Is a Major Determinant of Improved Long-Term Survival: FAST-MI (French Registry of Acute Coronary Syndrome)

https://doi.org/10.1016/j.jcin.2012.05.008Get rights and content
Under an Elsevier user license
open archive

Objectives

This study sought to assess the impact of invasive strategy (IS) versus a conservative strategy (CS) on in-hospital complications and 3-year outcomes in patients with non–ST-segment elevation myocardial infarction (NSTEMI) from the FAST-MI (French Registry of Acute Coronary Syndrome).

Background

Results from randomized trials comparing IS and CS in patients with NSTEMI are conflicting.

Methods

Of the 3,670 patients in FAST-MI, which included patients with acute myocardial infarction (within 48 h) over a 1-month period in France at the end of 2005, 1,645 presented with NSTEMI.

Results

Of the 1,645 patients analyzed, 80% had an IS. Patients in the IS group were younger (67 ± 12 years vs. 80 ± 11 years), less often women (29% vs. 51%), and had a lower GRACE (Global Registry of Acute Coronary Events) risk score (137 ± 36 vs. 178 ± 34) than patients treated with CS. In-hospital mortality and blood transfusions were significantly more frequent in patients with CS versus IS (13.1% vs. 2.0%, 9.1% vs. 4.6%). Use of IS was associated with a significant reduction in 3-year mortality and cardiovascular death (17% vs. 60%, adjusted hazard ratio [HR]: 0.44, 95% confidence interval [CI]: 0.35 to 0.55 and 8% vs. 36%, adjusted HR: 0.37, 95% CI: 0.27 to 0.50). After propensity score matching (181 patients per group), 3-year survival was significantly higher in patients treated with IS.

Conclusions

In a real-world setting of patients admitted with NSTEMI, the use of IS during the initial hospital stay is an independent predictor of improved 3-year survival, regardless of age. (French Registry of Acute Coronary Syndrome [FAST-MI]; NCT00673036)

Key Words

acute myocardial infarction
invasive strategy
non–ST-segment elevation myocardial infarction
percutaneous coronary intervention

Abbreviations and Acronyms

ACS
acute coronary syndromes
CAG
coronary angiogram
CI
confidence interval
CS
conservative strategy
HR
hazard ratio
IS
invasive strategy
MACE
major adverse cardiac event(s)
MI
myocardial infarction
NSTEMI
non– ST-segment elevation myocardial infarction
NSTE-ACS
non–ST-segment elevation acute coronary syndromes
PCI
percutaneous coronary intervention
STEMI
ST-segment elevation myocardial infarction
TIMI
Thrombolysis In Myocardial Infarction

Cited by (0)

FAST-MI is a registry from the French Society of Cardiology that is supported by unrestricted grants from Pfizer and Servier and an additional grant from the Caisse Nationale d'Assurance-Maladie-Travailleurs Salariés. Dr. Ducrocq has a relationship with Medtronic, Inc., AstraZeneca Pharmaceuticals, and Eli Lilly. Dr. Simon has received research grants from Pfizer and Servier for the FAST-MI registry; served as a board member for Bayer; and has given lectures to Sanofi and Lilly. Dr. Danchin has received research grants from AstraZeneca, Daiichi-Sankyo, Eli Lilly, GlaxoSmithKline, MSD, Novartis, Sanofi-Aventis, Servier, and The Medicines Company; and has served on advisory panels or received lecture fees from AstraZeneca, Boeheringer-Ingelheim, Bristol-Myers Squibb, Eli-Lilly, Menarini, Merck-Serono, Novo-Nordisk, Roche, Servier, and Sanofi-Aventis. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.